OPALE, the Organization
for Partnerships in Leukemia
The OPALE Carnot institute is a healthcare industry’s preferred partner for the research and development of innovative solutions aimed at diagnosis, treatment and follow-up of patients in the field of leukemia and related diseases, the deadliest blood cancer and first child cancer.
Unique leukemia R&D partnering opportunities
The OPALE Carnot Institute gives healthcare companies unique access to the expertise of an internationally unparalleled consortium in the field of leukemia and related diseases. Our aim is to prolong or save the lives of more patients by accelerating therapeutic and diagnostic innovation across the entire research and development value chain.
Explore our offer
Carnot, a label of excellence
Granted by the French Ministry of Higher Education, Research and Innovation, the Carnot label is prestigious and highly selective.
Being labelled Carnot is a guarantee of scientific and operational excellence in R&D collaborations for our industrial partners.
The Carnot institutes follow their namesake Charter to guarantee top-tier collaborative research, effectively driving industrial advancements while ensuring ongoing scientific revitalization within the Carnot community.
"The OPALE Carnot Institute addresses many of the needs of manufacturers in the leukemia market, thanks to the specialization and depth of its R&D offering, accessible through a one-stop shop."
Medical Director of a pharmaceutical company
Member of OPALE's Strategic Advisory Committee
"Accelerating the emergence of innovative solutions for the diagnosis, treatment, and follow-up of patients in the field of leukemia and related diseases"
Pr Hervé Dombret
OPALE's Chairman
News
Simplifying the Backbone to Accelerate AML Innovation: Insights from the French BIG-1 Study
19/12/2025
At ASH25, the French BIG-1 intergroup defines a simplified AML induction backbone designed to support robust therapeutic innovation.
> Read moreAcute Myeloid Leukemia Trials: Why the Next Breakthrough May Be a Better Endpoint
15/12/2025
What if the next major advance in AML trials wasn’t a new molecule but a better endpoint ?
> Read moreFrench AML Research at ASH: How National Consortia Are Shaping the Future of Leukemia Trials
05/12/2025
OPALE members present multiple AML and leukemia studies at ASH, highlighting the scientific impact of French national research consortia.
> Read more